Nasdaq · CIK 0001527352
NXL Nexalin Technology, Inc.
Insider trading from SEC Form 4. Last filing Dec 23, 2025. Close $3.36 on Oct 12, 2026, 0% from the 52-week low and -93% from the high.
In brief
Nexalin Technology, Inc. (NXL) has 15 SEC Form 4 filings on file from 8 insiders, the latest filed on Dec 23, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at NXL. The newest: David Owens (Chief Medical Officer) bought $1,095 of stock on Oct 28, 2024, filed Oct 30, 2024, scored 10 (weak).
1 Form 144 notice of planned sales is on file, the latest filed Sep 10, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Nexalin Technology, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | David Owens Chief Medical Officer buy | $1,095 500 shares | +0% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 10, 2025 | Elson Marilyn Associate to Affiliate | 23,150 1.35% of outstanding | $403 | Sep 10, 2025 | none |
Transactions
Every row filed, 21 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 19, 2025 | Alan Kazden director | AGrant or award Stock Option (right to buy)*derivative | +100,000 | $0.00 | $0 | 362,500 | Dec 23, 2025 |
| Dec 19, 2025 | Carolyn Hamby Shelton Sr. VP - Quality - Regulatory | AGrant or award Stock Option (right to buy)*derivative | +100,000 | $0.00 | $0 | 210,620 | Dec 23, 2025 |
| Dec 19, 2025 | David Owens Chief Medical Officer | AGrant or award Stock Option (right to buy)*derivative | +1,000,000 | $0.00 | $0 | 2,484,809 | Dec 23, 2025 |
| Dec 19, 2025 | Justin Van Fleet CFO | AGrant or award Stock Option (right to buy)*derivative | +100,000 | $0.00 | $0 | 230,435 | Dec 23, 2025 |
| Dec 19, 2025 | Mark White CEO | AGrant or award Stock Option (right to buy)*derivative | +1,000,000 | $0.00 | $0 | 2,387,024 | Dec 23, 2025 |
| Dec 19, 2025 | Ben Hu director | AGrant or award Stock Option (right to buy)*derivative | +100,000 | $0.00 | $0 | 100,000 | Dec 23, 2025 |
| Sep 29, 2025 | Leonard Osser owner | AGrant or award Common Stock | +83,333 | $0.00 | $0 | 1,618,577 | Sep 30, 2025 |
| Sep 29, 2025 | Ben Hu director | AGrant or award Common stock | +36,459 | $0.00 | $0 | 377,095 | Sep 30, 2025 |
| Sep 29, 2025 | Alan Kazden director | AGrant or award Common stockindirect: Owned by Alan and Natalie Kazden Family Trust | +36,459 | $0.00 | $0 | 119,590 | Sep 30, 2025 |
| Sep 29, 2025 | David Owens Chief Medical Officer | AGrant or award Common stock | +36,459 | $0.00 | $0 | 191,252 | Sep 30, 2025 |
| Sep 12, 2025 | David Owens Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +203,125 | $0.00 | $0 | 1,384,809 | Sep 12, 2025 |
| Sep 10, 2025 | Marilyn Elson owner | SOpen-market sale Common Stock Warrantsderivative | -23,150 | $0.02 | $403 | 112,850 | Sep 12, 2025 |
| Sep 12, 2025 | Carolyn Hamby Shelton Sr. VP - Quality - Regulatory | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 110,620 | Sep 12, 2025 |
| Sep 12, 2025 | David Owens Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 1,484,809 | Sep 12, 2025 |
| Jul 17, 2025 | Marilyn Elson owner | AGrant or award Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 286,000 | Jul 21, 2025 |
| Jul 17, 2025 | Marilyn Elson owner | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 316,000 | Jul 21, 2025 |
| Jul 17, 2025 | Marilyn Elson owner | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 346,000 | Jul 21, 2025 |
| Jul 17, 2025 | Marilyn Elson owner | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 376,000 | Jul 21, 2025 |
| Jul 17, 2025 | Marilyn Elson owner | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 406,000 | Jul 21, 2025 |
| Jul 17, 2025 | Marilyn Elson owner | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 436,000 | Jul 21, 2025 |
| Oct 28, 2024 | David Owens Chief Medical Officer | POpen-market purchase Common stock | +500 | $2.19 | $1,095 | 148,293 | Oct 30, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Marilyn Elsonowner, other
- Ben Hudirector
- Alan Kazdendirector
- Leonard Osserdirector, other, owner
- David OwensChief Medical Officer
- Carolyn Hamby SheltonSr. VP - Quality - Regulatory
- Justin Van FleetCFO
- Mark WhiteCEO
Questions about NXL
Answered from the filings on this page, as of the latest one.
Are insiders buying NXL?
No. In the last 90 days no insider at Nexalin Technology, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade NXL on the open market?
David Owens (Chief Medical Officer) bought $1,095 of NXL on Oct 28, 2024 and filed the Form 4 on Oct 30, 2024. InsiderTell scored 10 (weak).
How many insiders file Form 4 at Nexalin Technology, Inc.?
8 people have filed a Form 4 at Nexalin Technology, Inc., among them Marilyn Elson (10% owner), Ben Hu (director), Alan Kazden (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.